OPT: A costly price for vision
In the early days of investing I came across what I now understand as a speculative Biotech stock. Opthea Limited (OPT) at a market cap of just over AU$700 million was not a particularly small Biotech company by the time I had started to look into it. However the key here is that it relied all of its future value on one drug - OPT-302 which acted to block two members of the vascular endothelial growth factor family, namely VEGF-C and VEGF-D, which cause blood vessels to grow and leak. The promise it was selling was an alternative/combination treatment for the eye diseases wet aged macular degeneration (wet AMD) and diabetic macular oedema (DME).
âThe science behind the promising intervention/therapy always makes theoretical sense.â
So where did this company take me? As a newly-fledged doctor, a couple of days reading laboriously on the âbeauty of passive investingâ, and regrettably a dose of financial optimism that only a beginner could have, I became convinced by a Facebook post in a doctorâs investing forum that OPT was the next big thing. The science just seemed to make sense and previous trials (AMD Phase IIb & DME I) had shown reassuring results. However I would soon find out that my preconceived expertise in medicine and what I thought was an upper hand in understanding and digesting medical research was in fact my downfall. Like many biotech stocks that had come before it, some which succeed and plenty more that fail, the science behind the promising intervention/therapy always makes theoretical sense. For a potential therapy to get so far that institutional investors (with MD analysts under their employ) to value it at AU$700 million you best believe that the science makes sense. That understanding is already factored in the price. My misconception that only a handful of practising doctors who invested on the side could grasp the science allowed me to erroneously value a company which ultimately was based on speculation.
The amount I lost in the end is no small sum: $463.65 across 7 trades over 2 months (with free brokerage).Â
My investment into OPT relative to the S&P/ASX 200.
However I remain positive that I went through this exercise, having gained more experience and investing knowledge. Here is an outline of the trades and what I have learnt:
Trade 1 BUY @ $2.96 on 25/05/20 - I was under the belief that this stock was due to rise to $5.20 based on a Goldman Sachs price target and climbing prices secondary to the release of DME Phase IIa results. I learnt that price targets from analysts are not a sure thing and should be taken with a grain of salt. What is more important is understanding how they arrived at these targets, the timeframe for a share price to reach it and whether this aligns with your perspective.
Trade 2 BUY @ 3.28 on 05/06/20 - I bought at the peak of the price on the back of the DME Phase IIa trial results. While the results were generally positive they did not meet the optimistic expectations that many including myself were hoping for. The important thing with speculative stock is that they trade on the market expectations and even with a good result, if it is not as significant as the one that was anticipated, it will drop. And drop it did. I later learnt that a risk averse means of approaching this would be buy on the speculation, sell before the result.
Trade 3 BUY @ $2.56 on 26/06/20 - In an attempt to average down, I made this purchase at the lowest price of all the buy trades I made.
Trade 4 BUY at $2.63 on 23/07/20 - With the ASX announcement release that OPT would be presenting their DME IIa results at an international ophthalmology conference that weekend, the price once again rallied. I was hesitant to buy on this day but I finally made the commitment to practice what I had learnt from an earlier trade of âbuy on the speculation, sell before the resultâ. I assured myself that I would sell before the day was over.
Trade 5 SELL at $2.73 on 23/07/20 -Â I sold later that day at $0.10 higher than my buy price and made a small dent in securing back some of the losses I had made previously.
Trade 6 BUY at $2.79 on 27/07/20 - After reviewing the slides from the ophthalmology presentation I was convinced that the results showed a significant difference in treatment for a subset of patientâs who were refractory to previous treatment. I put in a sizeable percentage of the portfolio (~$4000). However once again I made the same mistake of misunderstanding the market expectation and that a significant result in a small patient population could justify a 16% rise in share price.
A significant difference between mean change in BCVA baseline at 8 weeks and 12 weeks follow-up appeared promising but as a I discovered a second time was not enough to satisfy the market.
Trade 7 SELL at $2.63 - I sold out of this one rather late, having told myself that I would put a stop loss at $2.70. However when it came to watching the price drop, refreshing, wishing it would change course, refreshing, further red, it can be quite overwhelming. The message is clear, this kind of short-term trading that relies on irrational greed and fear is not for me.Â
I have sold out my position in OPT and it does give me some relief. Just to reiterate I am $463.65 down and humbled. It may be a costly mistake but hopefully it is just a hurdle for my future in finding the value in investing. OPT will just be that wild rollercoaster Iâd have far more enjoyment watching from the safety of the ground.






















